MARKET

MRUS

MRUS

Merus
NASDAQ
20.97
+0.69
+3.40%
After Hours: 20.97 0 0.00% 16:01 10/06 EDT
OPEN
20.28
PREV CLOSE
20.28
HIGH
21.06
LOW
20.04
VOLUME
175.03K
TURNOVER
0
52 WEEK HIGH
33.09
52 WEEK LOW
13.47
MARKET CAP
962.07M
P/E (TTM)
-16.1419
1D
5D
1M
3M
1Y
5Y
Merus Announces Poster Presentation On MCLA-129 At 34th EORTC/NCI/AACR Symposium On Molecular Targets And Cancer Therapeutics On Oct. 28
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage
Benzinga · 09/07 20:13
Merus to Participate in a Panel Discussion at Citi's 17th Annual BioPharma Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bi...
GlobeNewswire · 09/01 12:00
Citigroup Cuts Price Target on Merus N.V to $34 From $37, Keeps Buy Rating
Citigroup Cuts Price Target on Merus N.V to $34 From $37, Keeps Buy Rating
MT Newswires · 08/17 10:54
Recap: Merus Q2 Earnings
  Merus (NASDAQ:MRUS) reported its Q2 earnings results on Monday, August 8, 2022 at 05:00 PM. Here's what investors need to know about the announcement. Earnings Merus reported an EPS of $-0.13.
Benzinga · 08/09 03:25
Merus N.V. (MRUS) Reports Q2 Loss, Tops Revenue Estimates
Merus N.V. (MRUS) delivered earnings and revenue surprises of 80% and 20.38%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/08 22:45
Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M
Merus press release (...
Seekingalpha · 08/08 21:38
Merus Q2 EPS $(0.13) Up From $(0.71) YoY, Sales $12.68M Up From $12.38M YoY
Merus (NASDAQ:MRUS) reported quarterly losses of $(0.13) per share. This is a 81.69 percent increase over losses of $(0.71) per share from the same period last year. The company reported $12.68 million in sales this
Benzinga · 08/08 20:23
Merus Announces Financial Results for the Second Quarter and Provides Business Update
- Clinical update of zenocutuzumab (Zeno) presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - Zeno represents a potential new standard of care for NRG1+ cancer - Clinical update of MCLA-129 planned for second half of 2022; e...
GlobeNewswire · 08/08 20:17
More
About MRUS
Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products include, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as well as MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.

Webull offers kinds of Merus NV stock information, including NASDAQ:MRUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRUS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRUS stock methods without spending real money on the virtual paper trading platform.